We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-11.1%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$55.3M
AUM Growth
-$12.3M
Cap. Flow
-$3.77M
Cap. Flow %
-6.81%
Top 10 Hldgs %
62.56%
Holding
65
New
2
Increased
18
Reduced
1
Closed
10
Avg Time Held Equity + Options
2.1 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
1.3 years
Avg Time Held Equity only
2.1 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.5 years

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$595K
2
AMRN icon
Amarin Corp
AMRN
+$297K
3
UTHR icon
United Therapeutics
UTHR
+$282K
4
ALKS icon
Alkermes
ALKS
+$253K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$64.5K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$868K
2
SRPT icon
Sarepta Therapeutics
SRPT
+$813K
3
BLUE icon
bluebird bio
BLUE
+$743K
4
INSM icon
Insmed
INSM
+$690K
5
PCRX icon
Pacira BioSciences
PCRX
+$489K

Sector Composition

Rank Sector Weight
1 Healthcare 56.66%
2 Miscellaneous 43.34%

No holdings matched the selected filter criteria.

1 2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opus Point Partners Management held 65 positions worth $55.3M, down 18% from $67.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management withdrew a net $3.77M in Q3 2019, closing 10 positions and reducing 1 holding. Its most notable exit was Immunomedics Inc, an estimated $868K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 59% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in United Therapeutics worth $279K.

  • Opus Point Partners Management's largest Q3 2019 buy was United Therapeutics: 3,498 shares worth $279K.
  • Opus Point Partners Management added most to Fortress Biotech in Q3 2019, an estimated $595K increase.
  • Opus Point Partners Management's biggest Q3 2019 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $131K.
  • Opus Point Partners Management fully exited Immunomedics Inc in Q3 2019, selling an estimated $868K.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $55.3M portfolio in Q3 2019.
  • Opus Point Partners Management opened 2 new positions and closed 10 in Q3 2019.
  • Opus Point Partners Management's portfolio value fell 18% quarter-over-quarter to $55.3M.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.